BKR beats on Q2 earnings and revenues, fueled by cost cuts, efficiency gains and strong IET segment performance.

KRP, NXRT and BEN made it to the Zacks Rank #1 (Strong Buy) income stocks list on July 23, 2025.

Stratasys (SSYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NextEra Energy (NEE) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.96 per share a year ago.

Suddenly, meme stocks — made famous by the 2021 GameStop saga — are back.

The Future of Ticketing, Streaming, and Events — Live Now and Ready to Scale The Future of Ticketing, Streaming, and Events — Live Now and Ready to Scale

The last time Meta Platforms, Inc. failed to surpass the quarterly consensus EPS forecast was in FQ4 2022. Since then, the company has delivered an impressive streak of dual beats. Mark Zuckerberg is known for his ability to create strong narratives, and I expect him to shine again during the Q2 earnings call. META stock is not currently overbought, which is another clear positive ahead of what is expected to be a strong earnings release.

AT&T Inc.'s Q2 outperformance and raised FY25 guidance in certain service components reinforce operational durability heading into a tough 2H25 set-up due to tariff-driven macro uncertainties. Despite robust acceleration in core consumer mobility and broadband subscriptions, which indicate value accretion underpinned by share gains and sustained ARPU expansion, AT&T likely anticipates stiffening tariff strain on margins. This is evident in the limited impact on its FY25 adjusted EBITDA guidance, despite expectations for up to $2 billion in incremental tax savings this year.

PROP sharpens its DJ Basin growth plan with a disciplined cash flow model and over 10% production growth target.

HLT beats Q2 estimates as fee growth and global expansion lift results despite RevPAR softness and travel headwinds.

Stock Yards Bancorp (SYBT) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.94 per share a year ago.

PROG Holdings (PRG) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.92 per share a year ago.

United Community Banks (UCB) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.58 per share a year ago.

Amazon reported that its annual Prime Day promotion (July 8 to 11) generated record U.S. sales this year, a reasonable brag in the context of a skittish consumer economy. But the real story about Prime Day—now ten years old—is how it has reshaped the retail landscape and how major competitors like Walmart have learned how to take advantage of the trail Amazon blazed.

SUNNYVALE, Calif.--(BUSINESS WIRE)--Knightscope, Inc. (NASDAQ: KSCP), a leader in autonomous security robots and emergency communication devices, today announced that it has surpassed another $1.3 million in new contracts, including major client renewals, strategic expansions, and new sales wins nationwide. This growth underscores the sustained demand for smarter and more secured environments. Nationwide Emergency Communication Devices Growth Knightscope locked in major new wins in the aviation.

SAN DIEGO and CALGARY, AB , July 23, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal (GI) cancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion.

NanoViricides (NYSE-A:NNVC) said on Wednesday that its broad-spectrum antiviral candidate NV-387 has shown strong preclinical efficacy against multiple viruses, positioning it as a potential tool in global pandemic preparedness. The Connecticut-based biotech firm said its NV-387 compound has demonstrated effectiveness in animal studies against a wide range of viral threats, including MPox, Smallpox, Measles, Influenza, Coronaviruses, and other orthopoxviruses.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% in its stock price.

Intuitive Surgical's second-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.

Travelzoo (TZOO) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.23 per share a year ago.